相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。High-Z-Sensitized Radiotherapy Synergizes with the Intervention of the Pentose Phosphate Pathway for In Situ Tumor Vaccination
Yuxiang Wang et al.
ADVANCED MATERIALS (2022)
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
Sunil S. Badve et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Fernanda G. Herrera et al.
CANCER DISCOVERY (2022)
Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy
Xiangru Feng et al.
SCIENCE BULLETIN (2021)
Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy
Yajie Sun et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small-Cell Lung Cancer
Lili Wang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Development of D-melittin polymeric nanoparticles for anti-cancer treatment
Shixian Lv et al.
BIOMATERIALS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy
Eric H. Bent et al.
NATURE COMMUNICATIONS (2021)
Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis
Hao Li et al.
NATURE COMMUNICATIONS (2021)
Zoledronic Acid-Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment
Zhusheng Huang et al.
ACS NANO (2021)
Genetically Encoding Light-Responsive Protein-Polymers Using Translation Machinery for the Multi-Site Incorporation of Photo-Switchable Unnatural Amino Acids
Bar Israeli et al.
ADVANCED FUNCTIONAL MATERIALS (2021)
Advances in Combining Radiation and Immunotherapy in Breast Cancer
Anthony T. Nguyen et al.
CLINICAL BREAST CANCER (2021)
Noncanonical Amino Acids for Hypoxia-Responsive Peptide Self-Assembly and Fluorescence
Binbin Hu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
Wenxiang Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine
Ying Wang et al.
BIOACTIVE MATERIALS (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression
Brandon Griess et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma
Kshama Gupta et al.
FRONTIERS IN ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Electron-Accepting Micelles Deplete Reduced Nicotinamide Adenine Dinucleotide Phosphate and Impair Two Antioxidant Cascades for Ferroptosis-Induced Tumor Eradication
Xuliang Guo et al.
ACS NANO (2020)
Metabolism of immune cells in cancer
Robert D. Leone et al.
NATURE REVIEWS CANCER (2020)
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
Zhenkun Zong et al.
DRUG DELIVERY (2019)
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Maxim Shevtsov et al.
FRONTIERS IN ONCOLOGY (2019)
Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1
Hairui Wang et al.
NANO LETTERS (2019)
Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
Nina D'Abreo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Fluorescent Labeling Method Re-Evaluates the Intriguing Thermoresponsive Behavior of Poly(acrylamide-co-acrylonitrile)s with Upper Critical Solution Temperatures
Chie Otsuka et al.
MACROMOLECULES (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Hari Menon et al.
FRONTIERS IN IMMUNOLOGY (2019)
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells
Yaqi Lv et al.
ACS NANO (2018)
Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics
Shawn Stapleton et al.
ACS NANO (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects
Lingtong Meng et al.
ACS NANO (2018)
Hypoxia-responsive block copolymer radiosensitizers as anticancer drug nanocarriers for enhanced chemoradiotherapy of bulky solid tumors
Wei Yin et al.
BIOMATERIALS (2018)
Thermo- and pH-dual responsive polymeric micelles with upper critical solution temperature behavior for photoacoustic imaging-guided synergistic chemo-photothermal therapy against subcutaneous and metastatic breast tumors
Zhe Yang et al.
THERANOSTICS (2018)
Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy
Lei Hua et al.
THERANOSTICS (2018)
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
T. Kordbacheh et al.
ANNALS OF ONCOLOGY (2018)
Macrophage Immunometabolism: Where Are We (Going)?
Jan Van den Bossche et al.
TRENDS IN IMMUNOLOGY (2017)
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
David Kung-Chun Chiu et al.
NATURE COMMUNICATIONS (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells
Zhe Yang et al.
JOURNAL OF MATERIALS CHEMISTRY B (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
NADPH Oxidases Are Essential for Macrophage Differentiation
Qing Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Metabolomics: beyond biomarkers and towards mechanisms
Caroline H. Johnson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm et al.
NATURE REVIEWS MATERIALS (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
Radioimmunotherapy of human tumours
Steven M. Larson et al.
NATURE REVIEWS CANCER (2015)
Metabolism of stromal and immune cells in health and disease
Bart Ghesquiere et al.
NATURE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Felix Klug et al.
CANCER CELL (2013)
ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages
Yan Zhang et al.
CELL RESEARCH (2013)
Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity
Yoko Kidani et al.
NATURE IMMUNOLOGY (2013)
The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation
Ruoning Wang et al.
IMMUNITY (2011)
Clinical radioimmunotherapy-the role of radiobiology
Jean-Pierre Pouget et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)